S&P 500   3,246.59 (+0.30%)
DOW   26,815.44 (+0.20%)
QQQ   265.39 (+0.47%)
AAPL   108.22 (+1.03%)
MSFT   203.19 (+1.30%)
FB   249.53 (+0.20%)
GOOGL   1,422.86 (+0.96%)
AMZN   3,019.79 (+0.66%)
NVDA   493.92 (+1.85%)
TSLA   387.79 (+1.95%)
BABA   269.73 (-1.18%)
CGC   14.27 (-2.26%)
GE   6.06 (-0.82%)
MU   49.47 (-0.76%)
AMD   75.82 (+1.46%)
T   28.04 (+0.61%)
F   6.66 (+0.30%)
ACB   5.20 (+0.58%)
GILD   62.25 (-1.33%)
NFLX   473.08 (+0.52%)
DIS   122.49 (-0.64%)
BAC   23.34 (+0.34%)
BA   146.05 (-3.39%)
S&P 500   3,246.59 (+0.30%)
DOW   26,815.44 (+0.20%)
QQQ   265.39 (+0.47%)
AAPL   108.22 (+1.03%)
MSFT   203.19 (+1.30%)
FB   249.53 (+0.20%)
GOOGL   1,422.86 (+0.96%)
AMZN   3,019.79 (+0.66%)
NVDA   493.92 (+1.85%)
TSLA   387.79 (+1.95%)
BABA   269.73 (-1.18%)
CGC   14.27 (-2.26%)
GE   6.06 (-0.82%)
MU   49.47 (-0.76%)
AMD   75.82 (+1.46%)
T   28.04 (+0.61%)
F   6.66 (+0.30%)
ACB   5.20 (+0.58%)
GILD   62.25 (-1.33%)
NFLX   473.08 (+0.52%)
DIS   122.49 (-0.64%)
BAC   23.34 (+0.34%)
BA   146.05 (-3.39%)
S&P 500   3,246.59 (+0.30%)
DOW   26,815.44 (+0.20%)
QQQ   265.39 (+0.47%)
AAPL   108.22 (+1.03%)
MSFT   203.19 (+1.30%)
FB   249.53 (+0.20%)
GOOGL   1,422.86 (+0.96%)
AMZN   3,019.79 (+0.66%)
NVDA   493.92 (+1.85%)
TSLA   387.79 (+1.95%)
BABA   269.73 (-1.18%)
CGC   14.27 (-2.26%)
GE   6.06 (-0.82%)
MU   49.47 (-0.76%)
AMD   75.82 (+1.46%)
T   28.04 (+0.61%)
F   6.66 (+0.30%)
ACB   5.20 (+0.58%)
GILD   62.25 (-1.33%)
NFLX   473.08 (+0.52%)
DIS   122.49 (-0.64%)
BAC   23.34 (+0.34%)
BA   146.05 (-3.39%)
S&P 500   3,246.59 (+0.30%)
DOW   26,815.44 (+0.20%)
QQQ   265.39 (+0.47%)
AAPL   108.22 (+1.03%)
MSFT   203.19 (+1.30%)
FB   249.53 (+0.20%)
GOOGL   1,422.86 (+0.96%)
AMZN   3,019.79 (+0.66%)
NVDA   493.92 (+1.85%)
TSLA   387.79 (+1.95%)
BABA   269.73 (-1.18%)
CGC   14.27 (-2.26%)
GE   6.06 (-0.82%)
MU   49.47 (-0.76%)
AMD   75.82 (+1.46%)
T   28.04 (+0.61%)
F   6.66 (+0.30%)
ACB   5.20 (+0.58%)
GILD   62.25 (-1.33%)
NFLX   473.08 (+0.52%)
DIS   122.49 (-0.64%)
BAC   23.34 (+0.34%)
BA   146.05 (-3.39%)
Log in
NASDAQ:ODT

Odonate Therapeutics Stock Forecast, Price & News

$13.00
-1.51 (-10.41 %)
(As of 09/24/2020 04:44 PM ET)
Add
Compare
Today's Range
$14.35
Now: $13.00
$15.36
50-Day Range
$14.56
MA: $24.12
$41.06
52-Week Range
$12.91
Now: $13.00
$46.50
Volume765,800 shs
Average Volume182,151 shs
Market Capitalization$417.65 million
P/E RatioN/A
Dividend YieldN/A
Beta0.58
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with locally advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.
Read More
Odonate Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 5.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.02 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ODT
CUSIPN/A
Phone858-731-8180

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$5.06 per share

Profitability

Net Income$-111,820,000.00

Miscellaneous

Employees117
Market Cap$417.65 million
Next Earnings Date11/4/2020 (Estimated)
OptionableNot Optionable
$13.00
-1.51 (-10.41 %)
(As of 09/24/2020 04:44 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ODT News and Ratings via Email

Sign-up to receive the latest news and ratings for ODT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Odonate Therapeutics (NASDAQ:ODT) Frequently Asked Questions

How has Odonate Therapeutics' stock price been impacted by Coronavirus?

Odonate Therapeutics' stock was trading at $25.93 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ODT stock has decreased by 49.9% and is now trading at $13.00.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Odonate Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Odonate Therapeutics in the last year. There are currently 1 sell rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Odonate Therapeutics
.

When is Odonate Therapeutics' next earnings date?

Odonate Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Odonate Therapeutics
.

How were Odonate Therapeutics' earnings last quarter?

Odonate Therapeutics Inc (NASDAQ:ODT) issued its quarterly earnings results on Thursday, July, 30th. The company reported ($1.09) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.98) by $0.11.
View Odonate Therapeutics' earnings history
.

What price target have analysts set for ODT?

2 analysts have issued 1 year target prices for Odonate Therapeutics' stock. Their forecasts range from $26.00 to $50.00. On average, they anticipate Odonate Therapeutics' share price to reach $38.00 in the next twelve months. This suggests a possible upside of 192.3% from the stock's current price.
View analysts' price targets for Odonate Therapeutics
.

Are investors shorting Odonate Therapeutics?

Odonate Therapeutics saw a increase in short interest in August. As of August 31st, there was short interest totaling 1,550,000 shares, an increase of 58.3% from the August 15th total of 979,200 shares. Based on an average trading volume of 312,200 shares, the days-to-cover ratio is currently 5.0 days. Approximately 6.0% of the company's shares are sold short.
View Odonate Therapeutics' Short Interest
.

Who are some of Odonate Therapeutics' key competitors?

What other stocks do shareholders of Odonate Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Odonate Therapeutics investors own include Exelixis (EXEL), Boeing (BA), Bausch Health Companies (BHC), Fate Therapeutics (FATE), Viking Therapeutics (VKTX), AbbVie (ABBV), Apellis Pharmaceuticals (APLS), Athenex (atnx), BioCryst Pharmaceuticals (BCRX) and Crispr Therapeutics (CRSP).

Who are Odonate Therapeutics' key executives?

Odonate Therapeutics' management team includes the following people:
  • Mr. Kevin C. Tang, Chairman & CEO (Age 52)
  • Mr. John G. Lemkey, Chief Operating Officer (Age 38)
  • Dr. Joseph P. O'Connell M.D., Chief Medical Officer (Age 65)
  • Mr. Michael S. Hearne, CFO & Principal Accounting Officer (Age 57)
  • Dr. Steven S. Pfeiffer Ph.D., VP of Technical Operations (Age 43)

When did Odonate Therapeutics IPO?

(ODT) raised $150 million in an IPO on Thursday, December 7th 2017. The company issued 5,900,000 shares at $24.00-$27.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and Cowen was co-manager.

What is Odonate Therapeutics' stock symbol?

Odonate Therapeutics trades on the NASDAQ under the ticker symbol "ODT."

Who are Odonate Therapeutics' major shareholders?

Odonate Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Driehaus Capital Management LLC (2.45%), Vanguard Group Inc. (2.12%), RTW Investments LP (1.50%), Opaleye Management Inc. (0.78%), Charles Schwab Investment Management Inc. (0.25%) and FMR LLC (0.22%). Company insiders that own Odonate Therapeutics stock include Aaron I Davis, Boxer Capital, Llc, Jeff L Vacirca and Kevin C Tang.
View institutional ownership trends for Odonate Therapeutics
.

Which major investors are selling Odonate Therapeutics stock?

ODT stock was sold by a variety of institutional investors in the last quarter, including Opaleye Management Inc., FMR LLC, FMR LLC, California Public Employees Retirement System, PDT Partners LLC, Strs Ohio, Chartwell Investment Partners LLC, and Virtus ETF Advisers LLC.
View insider buying and selling activity for Odonate Therapeutics
.

Which major investors are buying Odonate Therapeutics stock?

ODT stock was bought by a variety of institutional investors in the last quarter, including RTW Investments LP, Driehaus Capital Management LLC, Assenagon Asset Management S.A., Jacobs Levy Equity Management Inc., Federated Hermes Inc., Bessemer Group Inc., Goldman Sachs Group Inc., and Vanguard Group Inc.. Company insiders that have bought Odonate Therapeutics stock in the last two years include Aaron I Davis, Boxer Capital, Llc, Jeff L Vacirca, and Kevin C Tang.
View insider buying and selling activity for Odonate Therapeutics
.

How do I buy shares of Odonate Therapeutics?

Shares of ODT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Odonate Therapeutics' stock price today?

One share of ODT stock can currently be purchased for approximately $13.00.

How big of a company is Odonate Therapeutics?

Odonate Therapeutics has a market capitalization of $417.65 million. The company earns $-111,820,000.00 in net income (profit) each year or ($4.05) on an earnings per share basis. Odonate Therapeutics employs 117 workers across the globe.

What is Odonate Therapeutics' official website?

The official website for Odonate Therapeutics is www.odonate.com.

How can I contact Odonate Therapeutics?

Odonate Therapeutics' mailing address is 4747 EXECUTIVE DRIVE SUITE 510, SAN DIEGO CA, 92121. The company can be reached via phone at 858-731-8180 or via email at [email protected]

This page was last updated on 9/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.